Impact of advanced therapy initiation on antibiotic dependence in chronic pouchitis
Inflammatory Bowel Diseases · 2026
DOI: 10.1093/ibd/izag086 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, 2026. Verfasst von Yushan Pan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, United States. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Colitis, Ulcerative, Pouchitis, Proctocolectomy, Restorative. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
A quarter of patients with ulcerative colitis who undergo total proctocolectomy with ileal pouch–anal anastomosis experience chronic pouchitis. While advanced therapies (ATs) are effective in some patients, their impact on antibiotic dependence is unclear.
Methods
In a multicenter, retrospective study, we identified adults with chronic pouchitis during treatment with AT. Those with complete pre-AT antibiotic data formed the “incident AT user” cohort. Those with only post-AT data formed the “prevalent AT user” cohort. Antibiotic prescription was modeled as percentage of time, calculated as the number of weeks of antibiotic prescription during the weeks of observed time. The pooled prevalence of antibiotic use during AT was calculated in a systematic review and meta-analysis,.
Results
Of the 67 incident AT users, 24 (36%) initiated treatment with tumor necrosis factor-α antagonist, 17 (25%) with anti-integrin, 23 (34%), with interleukin (IL) inhibitors (anti-IL), and 3 (5%) with Janus kinase inhibitors. The mean time on antibiotics was unchanged from 38% to 33% after AT initiation, and 61% of patients (n = 44) had a reduction in antibiotic use. Compared to the patients without reduction, the reduction group had a higher proportion of patients on anti-IL (46% vs 15%, adjusted odds ratio [OR] 11.1; 95% CI, 2.12-57.62). There were no differences in disease-related parameters. Seventy-nine percent (22/28) of prevalent AT users required antibiotics. On meta-analysis, pooled prevalence of antibiotic use was 0.46 (95% CI, 0.35-0.57).
Conclusions
Just over half of patients on AT for chronic pouchitis saw reduced antibiotic use; however, further studies are needed to identify impact of AT on antibiotic use and define which patients benefit from immune-mediated vs microbiome-directed therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, United States.
- Division of Gastroenterology, Crohn's and Colitis Center, Massachusetts General Hospital, Boston, MA 02114, United States.
ORCID-Profile: Yushan Pan, Ashwin N Ananthakrishnan
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Pan, Y., Dunleavy, K. A., & Ananthakrishnan, A. N. (2026). Impact of advanced therapy initiation on antibiotic dependence in chronic pouchitis. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag086
Vancouver
Pan Y, Dunleavy KA, Ananthakrishnan AN. Impact of advanced therapy initiation on antibiotic dependence in chronic pouchitis. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag086
BibTeX
@article{Pan2026,
author = {Pan, Yushan and Dunleavy, Katie A and Ananthakrishnan, Ashwin N},
title = {Impact of advanced therapy initiation on antibiotic dependence in chronic pouchitis},
journal = {Inflammatory Bowel Diseases},
year = {2026},
doi = {10.1093/ibd/izag086}
}
EUVIMED